Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 1814.87
CCXI's Cash to Debt is ranked higher than
77% of the 1239 Companies
in the Global Biotechnology industry.

( Industry Median: 60.65 vs. CCXI: 1814.87 )
CCXI' s 10-Year Cash to Debt Range
Min: 6.43   Max: No Debt
Current: 1814.87

F-Score: 3
Z-Score: 12.05
M-Score: -6.59
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -1992.88
CCXI's Operating margin (%) is ranked higher than
55% of the 1013 Companies
in the Global Biotechnology industry.

( Industry Median: -78.59 vs. CCXI: -1992.88 )
CCXI' s 10-Year Operating margin (%) Range
Min: -731.32   Max: 31.55
Current: -1992.88

-731.32
31.55
Net-margin (%) -1970.72
CCXI's Net-margin (%) is ranked higher than
54% of the 1013 Companies
in the Global Biotechnology industry.

( Industry Median: -70.38 vs. CCXI: -1970.72 )
CCXI' s 10-Year Net-margin (%) Range
Min: -736.13   Max: 31.41
Current: -1970.72

-736.13
31.41
ROE (%) -32.48
CCXI's ROE (%) is ranked higher than
74% of the 1134 Companies
in the Global Biotechnology industry.

( Industry Median: -34.93 vs. CCXI: -32.48 )
CCXI' s 10-Year ROE (%) Range
Min: -42.81   Max: -4.02
Current: -32.48

-42.81
-4.02
ROA (%) -30.79
CCXI's ROA (%) is ranked higher than
72% of the 1239 Companies
in the Global Biotechnology industry.

( Industry Median: -28.51 vs. CCXI: -30.79 )
CCXI' s 10-Year ROA (%) Range
Min: -35.64   Max: -3.07
Current: -30.79

-35.64
-3.07
ROC (Joel Greenblatt) (%) -3417.80
CCXI's ROC (Joel Greenblatt) (%) is ranked higher than
59% of the 1212 Companies
in the Global Biotechnology industry.

( Industry Median: -442.83 vs. CCXI: -3417.80 )
CCXI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2774.11   Max: -167.29
Current: -3417.8

-2774.11
-167.29
» CCXI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

CCXI Guru Trades in Q4 2013

Chuck Royce 282,000 sh (New)
Jim Simons 387,880 sh (New)
» More
Q1 2014

CCXI Guru Trades in Q1 2014

Jim Simons 199,780 sh (-48.49%)
Chuck Royce 70,000 sh (-75.18%)
» More
Q2 2014

CCXI Guru Trades in Q2 2014

Chuck Royce 70,000 sh (unchged)
Jim Simons 54,900 sh (-72.52%)
» More
Q3 2014

CCXI Guru Trades in Q3 2014

Jim Simons 68,300 sh (+24.41%)
Chuck Royce 70,000 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with CCXI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.73
CCXI's P/B is ranked higher than
93% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 5.76 vs. CCXI: 1.73 )
CCXI' s 10-Year P/B Range
Min: 1.32   Max: 4.98
Current: 1.73

1.32
4.98
EV-to-EBIT -2.73
CCXI's EV-to-EBIT is ranked higher than
51% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CCXI: -2.73 )
CCXI' s 10-Year EV-to-EBIT Range
Min: -70.7   Max: -1.5
Current: -2.73

-70.7
-1.5
Current Ratio 10.59
CCXI's Current Ratio is ranked higher than
87% of the 1228 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. CCXI: 10.59 )
CCXI' s 10-Year Current Ratio Range
Min: 6.61   Max: 19.54
Current: 10.59

6.61
19.54
Quick Ratio 10.59
CCXI's Quick Ratio is ranked higher than
88% of the 1228 Companies
in the Global Biotechnology industry.

( Industry Median: 4.53 vs. CCXI: 10.59 )
CCXI' s 10-Year Quick Ratio Range
Min: 6.61   Max: 19.54
Current: 10.59

6.61
19.54

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.66
CCXI's Price/Net Cash is ranked higher than
95% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 64.50 vs. CCXI: 2.66 )
CCXI' s 10-Year Price/Net Cash Range
Min: 1.97   Max: 7.68
Current: 2.66

1.97
7.68
Price/Net Current Asset Value 2.66
CCXI's Price/Net Current Asset Value is ranked higher than
95% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 34.97 vs. CCXI: 2.66 )
CCXI' s 10-Year Price/Net Current Asset Value Range
Min: 1.96   Max: 7.64
Current: 2.66

1.96
7.64
Price/Tangible Book 1.73
CCXI's Price/Tangible Book is ranked higher than
95% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9.12 vs. CCXI: 1.73 )
CCXI' s 10-Year Price/Tangible Book Range
Min: 1.56   Max: 4.92
Current: 1.73

1.56
4.92
Earnings Yield (Greenblatt) -36.60
CCXI's Earnings Yield (Greenblatt) is ranked higher than
54% of the 1174 Companies
in the Global Biotechnology industry.

( Industry Median: -6.40 vs. CCXI: -36.60 )
CCXI' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0   Max: 0
Current: -36.6

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:2CX.Germany
Chemocentryx Inc was incorporated in the state of Delaware on November 8, 1996. The Company is a biopharmaceutical company engaged in discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. The Company targets the chemokine system, a network of molecules including chemokine ligands and their associated receptors, as well as related chemo-attractant receptors, all of which are known to drive inflammation. It currently has five drug candidates in clinical development. CCX168 —Targeting the chemoattractant receptor known as C5aR, CCX168 has successfully completed and reported positive clinical data from the first two steps of a three-step Phase II clinical trial for the treatment of anti-neutrophil cytoplasmic antibody, or ANCA, associated renal vasculitis, or AARV. CCX140 — Targeting the chemokine receptor known as CCR2, CCX140 is currently in Phase II clinical development in patients with diabetic nephropathy, a form of kidney disease. Vercirnon (also known as Traficet-EN, or CCX282) —Targeting the chemokine receptor known as CCR9, vercirnon is its drug candidate for the treatment of patients with moderate-to-severe Crohn's disease. CCX872 — its second generation orally administered inhibitor targeting CCR2, CCX872 is expected to complete Phase I clinical development. CCX507 — its second generation CCR9 inhibitor for the treatment of inflammatory bowel disease, or IBD, CCX507 is expected to complete Phase I clinical development. Its current drug candidates are manufactured using common chemical engineering and synthetic processes from readily available raw materials. It rely on contract manufacturing organizations to produce its drug candidates in accordance with the FDA's current good manufacturing practices, or cGMP, regulations for use in its clinical trials. The Company competes in the pharmaceutical, biotechnology and other related markets that address AARV, chronic kidney disease and diabetic nephropathy, IBD, rheumatoid arthritis, other autoimmune diseases and inflammatory disorders, and cancer. The Company competes with the pharmaceutical companies that currently sell or are developing drugs include AbbVie, Amgen, AstraZeneca, Biogen Idec, Bayer, Bristol-Myers Squibb, Elan, Roche/Genentech, GSK, Johnson & Johnson, Merck, Merck Serono, Takeda, Novartis, Pfizer, Sanofi and Teva. The Company and its manufacturers are subject to federal, state and local and foreign laws and regulations governing the use, generation, manufacture, storage, handling and disposal of these hazardous materials.
» More Articles for CCXI

Headlines

Articles On GuruFocus.com
Three Attractively Priced Small Cap Biotech Stocks Nov 05 2014 
New ipo recommended Sep 16 2012 

More From Other Websites
ChemoCentryx's CCX168, an Orally Administered Complement C5a Receptor Inhibitor, Granted Orphan-Drug... Nov 20 2014
CHEMOCENTRYX, INC. Financials Nov 18 2014
ChemoCentryx's Orally Administered C5aR Inhibitor CCX168 Shows Benefit in Non-Renal ANCA Vasculitis... Nov 17 2014
ChemoCentryx's Orally Administered C5aR Inhibitor CCX168 Shows Benefit in Non-Renal ANCA Vasculitis... Nov 17 2014
CHEMOCENTRYX, INC. Files SEC form 10-Q, Quarterly Report Nov 06 2014
ChemoCentryx to Present at Two Upcoming Investor Conferences Nov 06 2014
ChemoCentryx to Present at Two Upcoming Investor Conferences Nov 06 2014
ChemoCentryx posts 3Q loss Nov 06 2014
ChemoCentryx posts 3Q loss Nov 06 2014
CHEMOCENTRYX, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Nov 05 2014
ChemoCentryx Reports Third Quarter 2014 Financial Results and Provides Corporate Update Nov 05 2014
ChemoCentryx Reports Third Quarter 2014 Financial Results and Provides Corporate Update Nov 05 2014
Q3 2014 ChemoCentryx Inc Earnings Release - After Market Close Nov 05 2014
ChemoCentryx to Hold Third Quarter 2014 Financial Results Conference Call on Wednesday, November 5,... Oct 22 2014
ChemoCentryx to Hold Third Quarter 2014 Financial Results Conference Call on Wednesday, November 5,... Oct 22 2014
ChemoCentryx's Orally Administered CCR9 Inhibitor, CCX507, Shown to be Well Tolerated and Effective... Oct 21 2014
ChemoCentryx's Orally Administered CCR9 Inhibitor, CCX507, Shown to be Well Tolerated and Effective... Oct 21 2014
ChemoCentryx Releases Phase III SHIELD 4 Clinical Results in Patients With Crohn's Disease Oct 20 2014
ChemoCentryx Releases Phase III SHIELD 4 Clinical Results in Patients With Crohn's Disease Oct 20 2014
ChemoCentryx, Inc. (CCXI) in Focus: Stock Rises 9.6% Oct 17 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK